These benefits are reflected in the clinical guidelines published by the American Diabetes Association (ADA) and the American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE), which recommend use of a GLP-1RA or a sodium-glucose co-transporter-2 inhibitor (SGLT2i) with demonstrated CV risk reduction in patients with established/high risk of atherosclerotic CVD (ASCVD), while considering patient-specific factors [15, 17]
For those seeking to enhance their health, fitness goals or active lifestyles, levocarnitine supplementation deserves consideration
Thus, in principle, widespread GLP-1 use could reduce future healthcare burden from cardiovascular disease and diabetes complications
Seek immediate evaluation if any of the following occur: worsening vision, severe eye pain, fever, inability to move the eye normally, bulging of the eye, rapid spread of redness beyond the eyelid, or signs of systemic illness